Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$88.86 USD
-0.25 (-0.28%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $88.87 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.86 USD
-0.25 (-0.28%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $88.87 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.
Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.
Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.
Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked
by Zacks Equity Research
Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More
by Kinjel Shah
Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.
Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.
Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
by Zacks Equity Research
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.
Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease
by Zacks Equity Research
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
Epizyme (EPZM) Stock Dives on Public Offering of Common Stock
by Zacks Equity Research
Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Down 19% in 4 Weeks, Here's Why Axsome (AXSM) Looks Ripe for a Turnaround
by Zacks Equity Research
Axsome (AXSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study
by Zacks Equity Research
ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.